[1] Barré-Sinoussi F, Chermann JC, Rey F, Nugeyre MT, Chamaret S, Gruest J, Dauguet C, Axler-Blin C, Vézinet-Brun F, Rouzioux C, Rozenbaum W, Montagnier L. Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS) . Science , 1983, 220(4599): 868-871.
[2] Lu XF, Chen ZW. The development of anti-HIV-1 drugs . Acta Pharm Sin , 2010, 45(2): 165-176.
[3] Shaw GM, Hunter E. HIV transmission . Cold Spring Harb Perspect Med , 2012, 2(11): a006965.
[4] Gogtay JA, Malhotra G. Reformulation of existing antiretroviral drugs . Curr Opin HIV AIDS , 2013, 8(6): 550-555.
[5] Vallejo A, Valladares A, De Felipe B, Vivancos J, Gutierrez S, Soriano-Sarabia N, Ruiz-Mateos E, Lissen E, Leal M. High thymic volume is associated with viral replication and immunologic impairment only early after HAART interruption in chronic HIV infection . Viral Immunol , 2005, 18(4): 740-746.
[6] Carr A, Cooper DA. Adverse effects of antiretroviral therapy . Lancet , 2000, 356(9239): 1423-1430.
[7] Baalwa J, Wang SY, Parrish NF, Decker JM, Keele BF, Learn GH, Yue L, Ruzagira E, Ssemwanga D, Kamali A, Amornkul PN, Price MA, Kappes JC, Karita E, Kaleebu P, Sanders E, Gilmour J, Allen S, Hunter E, Montefiori DC, Haynes BF, Cormier E, Hahn BH, Shaw GM. Molecular identification, cloning and characterization of transmitted/founder HIV-1 subtype A, D and A/D infectious molecular clones . Virology , 2013, 436(1): 33-48.
[8] Xu HB, Wang XL, Veazey RS. Mucosal immunology of HIV infection . Immunol Rev , 2013, 254(1): 10-33.
[9] Boily MC, Baggaley RF, Wang L, Masse B, White RG, Hayes RJ, Alary M. Heterosexual risk of HIV-1 infection per sexual act: systematic review and meta-analysis of observational studies . Lancet Infect Dis , 2009, 9(2): 118-129.
[10] Keele BF. Identifying and characterizing recently transmitted viruses . Curr Opin HIV AIDS , 2010, 5(4): 327-334.
[11] Zhu T, Mo H, Wang N, Nam DS, Cao Y, Koup RA, Ho DD. Genotypic and phenotypic characterization of HIV-1 patients with primary infection . Science , 1993, 261(5125): 1179-1181.
[12] Bar KJ, Li H, Chamberland A, Tremblay C, Routy JP, Grayson T, Sun CX, Wang SY, Learn GH, Morgan CJ, Schumacher JE, Haynes BF, Keele BF, Hahn BH, Shaw GM. Wide variation in the multiplicity of HIV-1 infection among injection drug users . J Virol , 2010, 84(12): 6241- 6247.
[13] Frange P, Meyer L, Jung M, Goujard C, Zucman D, Abel S, Hochedez P, Gousset M, Gascuel O, Rouzioux C, Chaix ML. Sexually-transmitted/founder HIV-1 cannot be directly predicted from plasma or PBMC-derived viral quasispecies in the transmitting partner . PLoS One , 2013, 8(7): e69144.
[14] Lukashov VV, Goudsmit J. Founder virus population related to route of virus transmission: a determinant of intrahost human immunodeficiency virus type 1 evolution? J Virol , 1997, 71(3): 2023-2030.
[15] Kearney M, Maldarelli F, Shao W, Margolick JB, Daar ES, Mellors JW, Rao V, Coffin JM, Palmer S. Human immunodeficiency virus type 1 population genetics and adaptation in newly infected individuals . J Virol , 2009, 83(6): 2715-2727.
[16] Keele BF, Giorgi EE, Salazar-Gonzalez JF, Decker JM, Pham KT, Salazar MG, Sun CX, Grayson T, Wang SY, Li H, Wei XP, Jiang CL, Kirchherr JL, Gao F, Anderson JA, Ping LH, Swanstrom R, Tomaras GD, Blattner WA, Goepfert PA, Kilby JM, Saag MS, Delwart EL, Busch MP, Cohen MS, Montefiori DC, Haynes BF, Gaschen B, Athreya GS, Lee HY, Wood N, Seoighe C, Perelson AS, Bhattacharya T, Korber BT, Hahn BH, Shaw GM. Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection . Proc Natl Acad Sci USA , 2008, 105(21): 7552-7557.
[17] Salazar-Gonzalez JF, Bailes E, Pham KT, Salazar MG, Guffey MB, Keele BF, Derdeyn CA, Farmer P, Hunter E, Allen S, Manigart O, Mulenga J, Anderson JA, Swanstrom R, Haynes BF, Athreya GS, Korber BTM, Sharp PM, Shaw GM, Hahn BH.
